A photo of Lee Grimes.

Director, Cancer Pathology Program, Division of Experimental Hematology & Division of Pathology

Co-Leader, Program in Hematologic Malignancies of Cincinnati Children's Hospital Medical Center, Cancer and Blood Diseases Institute

Professor, UC Department of Pediatrics



Biography & Affiliation


Dr. Grimes has a broad background in hematopoiesis, molecular biology, and molecular oncology including modeling of hematopoiesis, myelopoiesis and leukemia. His work on the Growth factor independent-1 (Gfi1) transcriptional repressor protein has spanned the initial identification of Gfi1 in a model of leukemia and the role of Gfi1 in normal myeloid biology, to the identification of GFI1 mutations in patients with severe congenital neutropenia (SCN) and non-immune chronic idiopathic neutropenia of adults (NI-CINA). His work utilizes Gfi1 as a molecular probe to understand both normal myeloid development and innate immune action, as well as marrow failure and transformation.

Research Interests

Acute myelogenous leukemia; T-cell acute lymphoblastic leukemia; severe congenital neutropenia; hematopoiesis; myelopoiesis; lineage decision; transcription factor

Academic Affiliation

Professor, UC Department of Pediatrics


Experimental Hematology and Cancer Biology, Cancer and Blood Diseases, Immunobiology

Science Blog


PhD: Immunology and Molecular Pathology, University of Florida, Gainesville, FL.

Postdoctoral Fellow: Fox Chase Cancer Center.


Selected Publication

Single-cell analysis of mixed-lineage states leading to a binary cell fate choice. Olsson, A; Venkatasubramanian, M; Chaudhri, VK; Aronow, BJ; Salomonis, N; Singh, H; Grimes, HL. Nature. 2016; 537:698-702.

Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia. Adelman, ER; Huang, HT; Roisman, A; Olsson, A; Colaprico, A; Qin, T; Lindsley, RC; Bejar, R; Salomonis, N; Grimes, HL; et al. Cancer Discovery. 2019; 9:1080-1101.

Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. Duy, C; Teater, M; Garrett-Bakelman, FE; Lee, TC; Meydan, C; Glass, JL; Li, M; Hellmuth, JC; Mohammad, HP; Smitheman, KN; et al. Cancer Discovery. 2019; 9:872-889.

Clonal hematopoiesis of indeterminate potential and its impact on patient trajectories after stem cell transplantation. Park, DS; Akuffo, AA; Muench, DE; Grimes, HL; Epling-Burnette, PK; Maini, PK; Anderson, AR A; Bonsall, MB. PLoS Computational Biology. 2019; 15:e1006913-e1006913.

Time resolved quantitative phospho-tyrosine analysis reveals Bruton's Tyrosine kinase mediated signaling downstream of the mutated granulocyte-colony stimulating factor receptors. Dwivedi, P; Muench, DE; Wagner, M; Azam, M; Grimes, HL; Greis, KD. Leukemia. 2019; 33:75-87.

The Human Cell Atlas bone marrow single-cell interactive web portal. Hay, SB; Ferchen, K; Chetal, K; Grimes, HL; Salomonis, N. Experimental Hematology. 2018; 68:51-61.

SKI controls MDS-associated chronic TGF-beta signaling, aberrant splicing, and stem cell fitness. Muench, DE; Ferchen, K; Velu, CS; Pradhan, K; Chetal, K; Chen, X; Weirauch, MT; Colmenares, C; Verma, A; Salomonis, N; et al. Blood. 2018; 132:e24-e34.

The Molecular Signature of Megakaryocyte-Erythroid Progenitors Reveals a Role for the Cell Cycle in Fate Specification. Lu, Y; Xavier-Ferrucio, J; Wang, L; Zhang, P; Grimes, HL; Venkatasubramanian, M; Chetal, K; Aronow, B; Salomonis, N; Krause, DS. Cell Reports. 2018; 25:2083-2093.e4.

Pathobiological Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes. Hayashi, Y; Zhang, Y; Yokota, A; Yan, X; Liu, J; Choi, K; Li, B; Sashida, G; Peng, Y; Xu, Z; et al. Cancer Discovery. 2018; 8:1438-1457.

cellHarmony: Cell-level matching and holistic comparison of single-cell transcriptomes. DePasquale, EA K; Dexheimer, P; Schnell, D; Ferchen, K; Hay, S; Valiente-Alandí, Í; Blaxall, B; Grimes, L; Salomonis, N. 2018.